Susquehanna International Group, LLP Aldeyra Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

  • $688 Billion
  • Q2 2025

A detailed history of Susquehanna International Group, LLP transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 231,766 shares of ALDX stock, worth $1.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
231,766
Previous 65,308 254.88%
Holding current value
$1.27 Million
Previous $375,000 136.53%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
BUY
$1.42 - $5.48 $236,370 - $912,189
166,458 Added 254.88%
231,766 $887,000
Q1 2025

May 14, 2025
SELL
$4.7 - $6.98 $124,258 - $184,537
-26,438 Reduced 28.82%
65,308 $375,000
Q4 2024

Feb 14, 2025
BUY
$4.21 - $5.9 $270,761 - $379,452
64,314 Added 234.45%
91,746 $457,000
Q3 2024

Nov 14, 2024
BUY
$3.19 - $6.32 $34,034 - $67,428
10,669 Added 63.65%
27,432 $147,000
Q2 2024

Aug 15, 2024
SELL
$3.25 - $4.72 $75,250 - $109,286
-23,154 Reduced 58.01%
16,763 $55,000
Q1 2024

May 07, 2024
SELL
$2.77 - $4.22 $449,512 - $684,817
-162,279 Reduced 80.26%
39,917 $130,000
Q4 2023

Feb 14, 2024
SELL
$1.47 - $6.06 $204,644 - $843,636
-139,214 Reduced 40.78%
202,196 $709,000
Q3 2023

Nov 14, 2023
BUY
$6.11 - $8.16 $609,429 - $813,902
99,743 Added 41.27%
341,410 $2.28 Million
Q2 2023

Aug 11, 2023
SELL
$7.11 - $11.89 $6.09 Million - $10.2 Million
-856,501 Reduced 77.99%
241,667 $2.03 Million
Q1 2023

May 16, 2023
BUY
$5.77 - $9.93 $4.92 Million - $8.46 Million
852,019 Added 346.14%
1,098,168 $10.9 Million
Q4 2022

Feb 14, 2023
BUY
$5.08 - $7.09 $576,351 - $804,395
113,455 Added 85.5%
246,149 $1.71 Million
Q3 2022

Nov 14, 2022
BUY
$3.8 - $7.74 $229,717 - $467,898
60,452 Added 83.68%
132,694 $709,000
Q2 2022

Aug 15, 2022
BUY
$2.43 - $4.85 $74,183 - $148,060
30,528 Added 73.18%
72,242 $288,000
Q1 2022

May 16, 2022
SELL
$3.25 - $5.17 $291,765 - $464,131
-89,774 Reduced 68.28%
41,714 $185,000
Q4 2021

Feb 14, 2022
SELL
$3.5 - $9.63 $138,691 - $381,598
-39,626 Reduced 23.16%
131,488 $526,000
Q3 2021

Nov 15, 2021
BUY
$7.94 - $11.31 $433,960 - $618,148
54,655 Added 46.93%
171,114 $1.5 Million
Q2 2021

Aug 11, 2021
SELL
$10.44 - $14.85 $1.61 Million - $2.29 Million
-154,268 Reduced 56.98%
116,459 $1.32 Million
Q1 2021

May 17, 2021
BUY
$6.53 - $14.42 $1.27 Million - $2.81 Million
194,854 Added 256.82%
270,727 $3.22 Million
Q4 2020

Feb 16, 2021
BUY
$6.31 - $8.13 $392,778 - $506,068
62,247 Added 456.83%
75,873 $520,000
Q3 2020

Nov 16, 2020
SELL
$4.0 - $7.53 $26,584 - $50,044
-6,646 Reduced 32.78%
13,626 $101,000
Q2 2020

Aug 14, 2020
SELL
$1.97 - $5.05 $6,345 - $16,266
-3,221 Reduced 13.71%
20,272 $85,000
Q1 2020

May 15, 2020
BUY
$1.62 - $6.4 $10,131 - $40,025
6,254 Added 36.28%
23,493 $58,000
Q4 2019

Feb 14, 2020
SELL
$4.73 - $7.98 $55,766 - $94,084
-11,790 Reduced 40.61%
17,239 $100,000
Q3 2019

Nov 14, 2019
SELL
$4.41 - $6.12 $79,953 - $110,955
-18,130 Reduced 38.44%
29,029 $153,000
Q2 2019

Aug 16, 2019
BUY
$6.0 - $9.0 $8,214 - $12,321
1,369 Added 2.99%
47,159 $283,000
Q2 2019

Aug 14, 2019
BUY
$6.0 - $9.0 $177,144 - $265,716
29,524 Added 181.51%
45,790 $275,000
Q1 2019

May 15, 2019
SELL
$7.14 - $9.85 $65,473 - $90,324
-9,170 Reduced 36.05%
16,266 $147,000
Q4 2018

Feb 14, 2019
BUY
$7.26 - $13.29 $75,482 - $138,176
10,397 Added 69.13%
25,436 $211,000
Q3 2018

Nov 14, 2018
BUY
$6.8 - $14.35 $102,265 - $215,809
15,039 New
15,039 $208,000
Q2 2018

Aug 14, 2018
SELL
$6.95 - $9.18 $306,383 - $404,691
-44,084 Closed
0 $0
Q1 2018

May 15, 2018
BUY
$6.55 - $8.9 $288,750 - $392,347
44,084 New
44,084 $331,000

Others Institutions Holding ALDX

# of Institutions
132
Shares Held
34.9M
Call Options Held
244K
Put Options Held
51.6K
View Full List

About Aldeyra Therapeutics, Inc.

ALDX Quotes by TradingView
  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $321M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email